During Thursday’s trade, Shares of Facebook, Inc. (NASDAQ:FB), lost -0.38% to $105.67.
FB has finally decided to comply with the Belgium court’s ruling. The social media giant has had a tough time with Belgian regulators who were not so happy with the company’s practice of tracking people (even those who were not Facebook users or not logged in).
Per a recent Reuters report, Facebook will no longer be tracking non-registered users’ data in the region.
The company admitted to tracking data for the past five years by inserting a cookie called ‘Datr’ into the browser whenever a person visited the platform. Belgian authorities (or for that matter a number of other European countries) have vehemently opposed this practice as they believed it violated the domestic data protection policies.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Shares of Barrick Gold Corporation (NYSE:ABX), inclined 2.96% to $7.64, during its current trading session.
Barrick Gold Corporation, declared that it has designated J. Robert S. Prichard to the company’s Board of Directors.
Mr. Prichard is a distinguished leader with a broad range of executive experience in business, law, higher education and public service. He presently serves as Chairman of Torys LLP, BMO Financial Group and Metrolinx. Mr. Prichard was President of the University of Toronto from 1990 to 2000 and President and CEO of Torstar Corporation from 2002 to 2009. He has also taught Law at the University of Toronto, Harvard University and Yale University. Mr. Prichard is an Officer of the Order of Canada, a Member of the Order of Ontario and a Fellow of the Royal Society of Canada.
Barrick Gold Corporation produces and sells gold and copper. The company is also involved in exploration and mine development activities. It conducts mining, development and exploration, and other activities in various countries, counting the United States, Canada, Australia, Argentina, Chile, Peru, the Dominican Republic, Papua New Guinea, Tanzania, Zambia, and Saudi Arabia. Its principal properties comprise Cortez, Goldstrike, Pueblo Viejo, Lagunas Norte, Veladero, Zaldívar, and Lumwana mines; and its Pascua-Lama project.
Finally, Medtronic plc (NYSE:MDT), gained 2.85%, and is now trading at $78.26.
Medtronic, declared financial results for its second quarter of fiscal year 2016, which ended October 30, 2015.
The company stated second quarter worldwide revenue of $7.058 billion, an improvement of 6 percent. Foreign currency translation had a negative $452 million impact on revenue. As stated, revenue raised 62 percent when contrast to the $4.366 billion stated by Medtronic, Inc. in the second quarter of fiscal year 2015. As detailed in the financial plans comprised through the link at the end of this release, second quarter non-GAAP net income and diluted earnings per share (EPS) were $1.469 billion and $1.03, improvements of 45 percent and 1 percent, respectively. As stated, second quarter net income and diluted EPS were $520 million and $0.36, decreases of 37 percent and 57 percent, respectively. This decline in GAAP earnings was driven primarily by a non-recurring certain tax adjustment resulting from the company`s formerly revealed September 28, 2015, internal reorganization due to the Covidien integration, which allowed about $9.8 billion ($9.3 billion net of tax) of cash, cash equivalents, and investments in marketable debt and equity securities formerly held by U.S.-controlled non-U.S. auxiliaries to be available for general corporate purposes.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.